Lupin gets FDA approval for Vfend generic

SILVER SPRING, Md. — The Food and Drug Administration has approved Lupin’s U.S. subsidiary Gavis’ generic Vfend (voriconazole), the company announced Monday. The drug is indicated to treat invasive aspergillosis, esophageal candidiasis and other serious invasive fungal infections. 

 

Lupin’s generic will be available as 50- and 200-mg tablets, and as a 40-mg/mL oral suspension. The tablets had U.S. sales $92.8 million and the oral suspension had $15.9 million in sales, according to IMS Health estimates as of March 2016.